BRIP1 and breast cancer: A case presented by Kwapisz et al. [35] of a patient with BRIP1-mutated metastatic hormone receptor positive breast cancer demonstrated, however, a resolution of symptoms, significant decrease in CA15.3, and complete metabolic response on positron emission tomography-computed tomography scan after 8 months of olaparib treatment.